# Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

> **NCT00001512** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- B Cell Lymphoma
- Follicular Lymphoma
- Lymphoma

## Interventions

- **DRUG:** Id-KLH Vaccine
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT00001512
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-09-09
- **Primary completion:** 2010-03-05
- **Final completion:** 2010-03-05
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001512, "Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00001512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*